Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Annexon Q3 EPS $(0.25) Beats $(0.28) Estimate
Annexon, Inc. (ANNX) Discusses Vonaprument Phase III ARCHER II Trial in Geographic Atrophy - Slideshow
Annexon Eyes Q4 2026 Phase III Readout for Vision-Preserving GA Drug
Annexon, Inc. (ANNX) Discusses Vonaprument Phase III ARCHER II Trial in Geographic Atrophy Transcript
Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial
Annexon To Highlight Phase 3 ARCHER II Clinical Trial Program At Virtual Investor Event
HC Wainwright & Co. Maintains Buy on Annexon, Raises Price Target to $25
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
JP Morgan Maintains Overweight on Annexon, Raises Price Target to $15
Annexon: Preserving Patient Function Is The Real Investment Opportunity
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
Annexon, Inc. (ANNX) Virtual Business Update Call Transcript
Annexon to Participate in Upcoming September Investor Conferences
JP Morgan Maintains Overweight on Annexon, Raises Price Target to $14
What Annexon (ANNX)'s Dual-Endpoint ARCHER II Update Means For Shareholders
Annexon (ANNX) Q2 2026 Earnings Call Transcript
Annexon (ANNX), What Is Behind Its Latest Update?
Citizens Upgrades Annexon to Market Perform
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.